Xinhuosu® is the commercial brand name of Recombinant Human Brain Natriuretic Peptide for Injection, a recombinant peptide drug developed by Tibet Rhodiola Pharmaceutical. It vasodilates blood vessels, inhibits the renin‑angiotensin‑aldosterone system, promotes natriuresis and diuresis, and reduces cardiac preload and afterload to relieve dyspnea in heart failure patients.
Main Indications
Intravenous treatment for patients with acute decompensated heart failure who have dyspnea at rest or with minimal physical activity, NYHA class greater than II.
Clinical Research
A multicenter, randomized controlled Phase III trial in China demonstrated that recombinant human brain natriuretic peptide rapidly improves dyspnea and hemodynamic parameters in patients with acute decompensated heart failure;
A large Phase IV clinical study involving over 1400 Chinese patients confirmed its stable therapeutic effect and acceptable safety profile in real‑world heart failure population;
Long-term observational studies verified predictable hemodynamic benefits and manageable adverse events when administered following the recommended dosing regimen.
Common Side Effects
Severe but important risks: Symptomatic hypotension, serious arrhythmia;
Common mild adverse reactions: Headache, nausea, vomiting, transient renal function changes and injection site reactions.
Approval Status in China
Original drug Xinhuosu® (Recombinant Human Brain Natriuretic Peptide for Injection, specification: 0.5mg per vial) was officially approved for marketing in China in 2005. It is currently a prescription biologic drug included in China’s category B medical insurance catalogue.
Buy Xinhuosu (Recombinant Human Brain Natriuretic Peptide for Injection) online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
